Corporate News – Market Update
Fg Communities (FGC) closed the trading session down 0.64 % at 12:30 PM Central European Time on Wednesday, 21 April 2026. The current trading price is approximately USD 6.20 per share.
- Shares outstanding: 5.1 million.
- Market capitalization: USD 31.8 million.
- Volume in last 24 hours: USD 421.6 thousand.
- Year‑to‑date performance: The share price has fallen 22.01 % since the end of March 2026.
- Moving average (200 days): USD 7.70.
- 52‑week range: Highest price of USD 21.55 on 28 October 2025; lowest price of USD 4.18 on 7 April 2026.
Comparative Performance of Related Stocks
| Symbol | Recent 24‑hour change | Current price | Market cap |
|---|---|---|---|
| EYPT (Eyepoint) | –6.82 % | USD 0.40 | USD 37.9 million |
| CELU (Celularity) | +8.62 % | USD 1.26 | USD 37.6 million |
| ELWT (Elauwit Connection) | –1.24 % | USD 5.56 | USD 37.3 million |
| HBIO (Harvard Bioscience) | +3.09 % | USD 8.34 | USD 36.8 million |
| EXOZ (Exozymes) | +3.00 % | USD 4.12 | USD 37.1 million |
Company Overview – Fg Communities
Fg Communities, a subsidiary of the FG Financial Group Inc., is a U.S.–based reinsurance and asset‑management holding company. The firm specializes in collateralized and loss‑capped reinsurance, as well as merchant‑banking services. It partners with clients to allocate capital in innovative ways, leveraging a strong reputation in the financial sector.
Recent Filings – Celularity (CELU)
Celularity Inc. filed its latest quarterly and annual reports with the U.S. Securities and Exchange Commission. The filings cover the six‑month period ending 30 June 2026 and the fiscal year ending 31 December 2025. Key highlights include:
- Confirmation of non‑accelerated, smaller reporting entity status.
- Full compliance with all SEC reporting and disclosure obligations.
- Progress in cellular therapy development, biomaterials production, and contract manufacturing services.
- Plans to expand commercial operations and secure additional funding.
- Updated corporate governance information, including board composition and executive appointments.
These documents reinforce Celularity’s focus on advancing its therapeutic pipeline and strengthening its financial position within the competitive biotechnology landscape.
